||M, Tue, W, Th, F, Sat, Sun
||vWF-cleaving Protease Inhibitor
||Thrombotic Thrombocytopenic Purpura (TTP) is characterized by the acquired or congenital deficiency of ADAMTS-13 activity. An antibody inhibitor will be present in roughly half of the cases diagnosed with idiopathic TTP.
Early diagnosis is paramount. Left untreated, TTP has a mortality rate above 90%; however, rapid diagnosis and treatment with plasma exchange improve the mortality rate to below 20%.
ADAMTS-13 Inhibitor is an important test in the differentiation of acquired and congenital forms of TTP.
To maximize the clinical utility of this test, Machaon Diagnostics is offering ADAMTS-13 activity and inhibitor testing on a daily basis with clinical consultation.
Weekend testing is available to contracted clients. Please phone the lab for further information.